Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.16 USD | +0.20% | +1.68% | +122.29% |
Financials (USD)
Sales 2024 * | 96.88M | Sales 2025 * | 113M | Capitalization | 664M |
---|---|---|---|---|---|
Net income 2024 * | -23M | Net income 2025 * | -33M | EV / Sales 2024 * | 5.73 x |
Net cash position 2024 * | 109M | Net cash position 2025 * | 130M | EV / Sales 2025 * | 4.72 x |
P/E ratio 2024 * |
-29.4
x | P/E ratio 2025 * |
-24.1
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.46% |
Latest transcript on Y-mAbs Therapeutics, Inc.
1 day | +0.20% | ||
1 week | +1.68% | ||
Current month | -6.77% | ||
1 month | -6.59% | ||
3 months | +55.17% | ||
6 months | +188.21% | ||
Current year | +122.29% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Gad
FOU | Founder | 54 | 15-03-31 |
Michael Rossi
CEO | Chief Executive Officer | 53 | Nov. 05 |
Bo Kruse
DFI | Director of Finance/CFO | 52 | 16-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Gill
BRD | Director/Board Member | 69 | 17-11-30 |
Director/Board Member | 54 | 15-08-31 | |
James Healy
CHM | Chairman | 58 | 17-10-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 509 M€ | -.--% | ||
0.01% | 9 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-22 | 15.16 | +0.20% | 472,662 |
24-04-19 | 15.13 | +0.87% | 467,188 |
24-04-18 | 15 | -0.73% | 410,152 |
24-04-17 | 15.11 | -0.20% | 450,829 |
24-04-16 | 15.14 | +1.54% | 442,474 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+122.29% | 664M | |
+2.49% | 96.73B | |
-0.55% | 21.31B | |
-16.61% | 21.21B | |
-5.24% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- YMAB Stock